{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:18:50Z","timestamp":1783739930186,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pompe disease is a rare, severe genetic multisystem disorder. It was one of the first genetic muscle diseases to benefit from an innovative therapy\u2014enzyme replacement therapy (ERT)\u2014more than 15\u00a0years ago. Despite this progress, data on patient management in community healthcare settings remain scarce, yet essential to understanding the dual economic and clinical burden of the disease. In this context, the French national healthcare claims database offers a valuable resource for comprehensive data collection. To our knowledge, this study is the first to provide a detailed, patient-level analysis of healthcare resource utilization for patients with Pompe disease. Our objective was to estimate the number of patients receiving ERT with alglucosidase alfa (Myozyme\u00ae), describe their care pathways, and assess associated medical expenses in both community settings and healthcare facilities across France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Cases of Pompe disease were identified using the French national healthcare claims database aims for expensive drugs. All patients with at least one hospitalization for ERT with Myozyme\u00ae in France in 2022 were included. Healthcare resource utilization in 2022 was documented, and costs were assessed from the perspective of public health insurance. Costs drivers were analyzed using a generalised linear model. A supplementary analysis using 2023 data was also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 154 patients were analyzed, including 24 with classic infantile-onset Pompe disease (IOPD) and 130 with late-onset Pompe disease (LOPD), with a mean age of 48.0\u00a0years. The annual healthcare cost per patient was \u20ac232,117 for IOPD patients and \u20ac358,768 for LOPD patients, nearly 96% of the costs were incurred inside hospitals. In addition to the unit cost of Myozyme\u00ae and related hospitalization, ventilator dependence and female sex emerged as major cost drivers. The 2023 data confirmed the robustness of the main findings, showing no substantial year-specific variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides robust real-world data to assess both hospital and non-hospital costs associated with Pompe disease in patients treated with Myozyme\u00ae. With an average of 81.9 medical or paramedical consultations per year and 49\u00a0days of hospitalization in 2022, the clinical burden imposed by Pompe disease is substantial, yet essential for patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03866-2","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:02:14Z","timestamp":1761904934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medical expenses and care pathways of patients with Pompe receiving myozyme: an observational study based on the French national healthcare database"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-0206","authenticated-orcid":false,"given":"Alicia","family":"Le Bras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"De Lonlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pompe Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzeddine","family":"Arrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bedat-Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"B\u00e9hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise Bouhour Fatima","family":"Bouibede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Champeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Davion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Deibener-Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Demurger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Espil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Esselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Feillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Ghorab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Gorce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalil","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Hogrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Krim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Labarthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Lebeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Magot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Magy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Maillet-Vioud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Masingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Mention","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Nollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Not","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Noury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Orlikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Paricio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Prigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Ropars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Sole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Taithe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjib","family":"Taouagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Tardieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Toquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Touati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vandeputte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Walther-Louvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taissir","family":"Ziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"3866_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"3866_CR2","first-page":"3389","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R, Reuser AJJ. Glycogen Storage Disease Type II: Acid Alphaglucosidase (Acid Maltase) Deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle MD, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001. p. 3389\u2013420."},{"issue":"5","key":"3866_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2005.11.033.","journal-title":"J Pediatr"},{"issue":"4","key":"3866_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","volume":"66","author":"MLC Hagemans","year":"2006","unstructured":"Hagemans MLC, Hop WJC, Van Doorn PA, Reuser AJJ, Van der Ploeg AT. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology. 2006;66(4):581\u20133. https:\/\/doi.org\/10.1212\/01.wnl.0000198776.53007.2c.","journal-title":"Neurology"},{"key":"3866_CR5","unstructured":"Commission europ\u00e9enne. D\u00e9cision d\u2019ex\u00e9cution (UE) 2023\/160485 de la Commission du 22 septembre 2023 relative \u00e0 l\u2019inscription dans le registre des m\u00e9dicaments \u00e0 usage humain (ANX_160485_fr). 2023. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230922160485\/anx_160485_fr.pdf."},{"issue":"2","key":"3866_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HMP van den Hout","year":"2003","unstructured":"van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332\u201340. https:\/\/doi.org\/10.1542\/peds.112.2.332.","journal-title":"Pediatrics"},{"issue":"6","key":"3866_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini C, De Antonio M, Taouagh N, et al. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe registry. J Inherit Metab Dis. 2020;43(6):1219\u201331. https:\/\/doi.org\/10.1002\/jimd.12272.","journal-title":"J Inherit Metab Dis"},{"issue":"19","key":"3866_CR8","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u201367. https:\/\/doi.org\/10.1212\/WNL.0000000000008441.","journal-title":"Neurology"},{"key":"3866_CR9","unstructured":"Assurance Maladie. Base des M\u00e9dicaments et Informations Tarifaires\u201d [Online]. http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index_presentation.php. [Accessed: 12-JUL-2022]."},{"issue":"6","key":"3866_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768-e31. https:\/\/doi.org\/10.1111\/ene.13285.","journal-title":"Eur J Neurol"},{"issue":"4","key":"3866_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41669-019-0142-3","volume":"3","author":"B Schoser","year":"2019","unstructured":"Schoser B, Hahn A, James E, Gupta D, Gitlin M, Prasad S. A systematic review of the health economics of Pompe disease. PharmacoEcon Open. 2019;3(4):479\u201393. https:\/\/doi.org\/10.1007\/s41669-019-0142-3.","journal-title":"PharmacoEcon Open"},{"issue":"39","key":"3866_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess Winch Engl. 2012;16(39):1\u2013543. https:\/\/doi.org\/10.3310\/hta16390.","journal-title":"Health Technol Assess Winch Engl"},{"issue":"3","key":"3866_CR13","doi-asserted-by":"publisher","first-page":"S774","DOI":"10.1007\/s11606-014-2885-y","volume":"29","author":"E Winquist","year":"2014","unstructured":"Winquist E, Coyle D, Clarke JTR, et al. Application of a policy framework for the public funding of drugs for rare diseases. J Gen Intern Med. 2014;29(3):S774-779. https:\/\/doi.org\/10.1007\/s11606-014-2885-y.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"3866_CR14","first-page":"182","volume":"5","author":"J Guo","year":"2012","unstructured":"Guo J, Kelton CML, Guo JJ. Recent developments, utilization, and spending trends for pompe disease therapies. Am Health Drug Benefits. 2012;5(3):182\u20139.","journal-title":"Am Health Drug Benefits"},{"key":"3866_CR15","unstructured":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France P Tuppin, J Rudant, P Constantinou Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique, 2017."},{"key":"3866_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey G, Jougla E, Fouillet A, H\u00e9mon D. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33. https:\/\/doi.org\/10.1186\/1471-2458-9-33.","journal-title":"BMC Public Health"},{"key":"3866_CR17","unstructured":"Available at: https:\/\/www.em-consulte.com\/revue\/RESPE\/65\/S4\/table-des-matieres\/. [Accessed September 2024]."},{"key":"3866_CR18","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. https:\/\/www.R-project.org)."},{"issue":"9","key":"3866_CR19","doi-asserted-by":"publisher","first-page":"e966","DOI":"10.1212\/WNL.0000000000207547","volume":"101","author":"C Lefeuvre","year":"2023","unstructured":"Lefeuvre C, De Antonio M, Bouhour F, et al. Characteristics of patients with late-onset Pompe disease in France: insights from the French Pompe registry in 2022. Neurology. 2023;101(9):e966\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000207547.","journal-title":"Neurology"},{"key":"3866_CR20","unstructured":"European Central Bank. Euro foreign exchange reference rates: Annual average exchange rates. 2023. https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/index.en.html."},{"key":"3866_CR21","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index\u2013all urban consumers (CPI-U), 2023; 1913\u20132023. https:\/\/www.bls.gov\/cpi\/."},{"issue":"1","key":"3866_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13023-023-02715-4","volume":"18","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van der Beek NAME, Brusse E, van der Ploeg AT, van den Hout JMP, Huidekoper HH. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study. Orphanet J Rare Dis. 2023;18(1):108. https:\/\/doi.org\/10.1186\/s13023-023-02715-4.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03866-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03866-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03866-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:02:17Z","timestamp":1761904937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03866-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03866-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The French public institution conducting this study has permanent access to the national claims database, in accordance with Articles R. 1461\u201312 et seq. of the French Public Health Code and the French Data Protection Authority (CNIL) decision CNIL-2016\u2013316. This study is registered on the Health Data Hub website (No. 20071826).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.\n                      Informed consent\n                      There was no patient involvement in the design of the study. Consequently, no informed consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pascal Lafor\u00eat received fees for participation to scientific boards by AMICUS Therapeutics, Sanofi Genzyme, Spark Therapeutics, consulting fees by Sanofi Genzyme, BioMarin, Sanofi Genzyme, Spark Therapeutics and sponsoring for scientific congress by Sanofi Genzyme, Amicus Therapeutics, Spark Therapeutics. Isabelle Durand-Zaleski received fees for participation to scientific boards by Air Liquide, BMS, Janssen, MSD, Pfizer, Sanofi Genzyme. Alicia Le Bras, Pascale De Lonlay, Shahram Attarian and Ana\u00efs Brassier have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"554"}}